Chromium(III) propionate complex supplementation improves carbohydrate metabolism in insulin-resistance rat model.

The purpose of this study was to evaluate the antidiabetic potential and safety of the chromium(III) propionate complex (CrProp) in insulin resistance induced by a high-fructose diet in rats. The experiment was carried out on 32 nine-week old male Wistar rats divided into 4 groups of 8 rats each. Animals were fed at libitum: the control diet (AIN-93M), and high-fructose diets (HF) containing various levels of Cr(III) given as CrProp (1 mg Cr kg(-1) diet (HF) and supplemented with 10 mg Cr kg(-1) diet (HFCr10), or 50 mg Cr kg(-1) diet (HFCr50), equal to approx. 0.1, 1 and 5 mg kg(-1) body mass per day) for 8 weeks. It was found that supplemental CrProp improved carbohydrate metabolism indices (decreasing serum insulin levels and insulin resistance indices HOMA-IR and HOMA-B, while increasing insulin sensitivity index QUICKI). Supplemental CrProp did not affect overall nutritional indices, blood morphology, most of the toxicity indices, blood glucose and lipids levels, while it increased kidney Cr level (HFCr50), normalized decreased liver Cu concentrations, and decreased kidney Fe and Cu levels (HFCr50). Supplemental CrProp administered at 10- and 50-fold doses of the basal dietary Cr level has a significant antidiabetic effect in insulin resistant rats. However, a prolonged treatment with this compound can affect Fe status. Copyright (c) 2010 Elsevier Ltd. All rights reserved.